Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Disclosure of interest: Nothing to disclose Poster Session I - RECOVERY, REHABILITATION AND OUTCOME 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.03 - PROGNOSIS AND OUTCOME AFTER STROKE P262 - ESOC25-1312 DISCHARGE RATES TO HOME FOLLOWING RECURRENT ISCHEMIC STROKE (IS): A REAL-WORLD DATA ANALYSIS ON THE CURRENT PATIENT JOURNEY IN THE US Mark Alberts 1 , Jenny Jiang 2 , Yan Wang 3 , Arimanda Reddy 4 , Haitham Alabsi 5 , Meg Thompson 5 , Merena Henderson 2 , Xiaoyan Li 2 , Priyanka Gaitonde 2 1 Hartford HealthCare, Hartford, United States, 2 Bristol Myers Squibb, Lawrenceville, United States, 3 Analysis Group Inc., Los Angeles, United States, 4 Mu-Sigma, Chicago, United States, 5 Johnson & Johnson, Raritan, United States Background and Aims: A significant proportion of IS patients experience recurrent IS within five years
Methods: We conducted a nested case-control study within a prospective cohort of 194 patients with acute ischemic stroke, 73 of whom met the inclusion criteria
We use both lab tests and clinical checks to see if the treatment works
BPC-157 works in the body through proposed repair pathways that involve blood vessel growth, cell movement, inflammation control, and tissue-protective signaling, but most evidence comes from animal and laboratory studies rather than confirmed human trials
If you are interested in trying BPC-157, call or complete the Book Now Form for more information
The FDA regulates medications to ensure their safety and efficacy before they can be marketed and prescribed to patients
US$ 21.95
US$ 28.50
.png)
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 21.60
